S754
Clinical - Lung
ESTRO 2026
metastasis-free survival time was 16 months. During the follow-up period, local/regional recurrence was detected in 5 (33%) patients, while distant metastasis was reported in 8 (53%) patients. Both local and distant recurrence were observed more in the PIV-high group than in the PIV-low group, but this did not reach a statistically significant level. Conclusion: Trimodal therapy could be applied to patients with locally advanced MPM with acceptable side effects to reduce local recurrences and is a safe treatment option. In this patient group, where distant recurrences have a clear negative effect on treatment results, it would be appropriate to confirm our results with larger studies and to investigate the synergistic effects of combined application with immunotherapies on treatment results. Keywords: Mesothelioma, Pleural decotication, Radiotherapy High-dose Radiation Therapy for Limited-Stage Small-Cell Lung Cancer: Real-World Experience from Two Tertiary Centers bilal krayim 1 , oded icht 2 , aaron allen 1 , nir peled 1 , mor moskovitz 2 1 helmsley cancer center, shaare zedek medical center, jerusalem, Israel. 2 1. Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel, Petach Tikva, Israel Digital Poster 194
hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma: a multicentre, phase 2-3, randomised, controlled trial. Lancet Oncol. 2019;20(8):1148-1159. Keywords: Intratumoral, Radioenhancer, Stage III NSCLC
Digital Poster 186
Local Control Rates and Side Effects in Malignant Pleural Mesothelioma Treated with Intensity- Modulated Radiotherapy After Pleural Decortication Fatma Sert 1 , Ezgi Aslan 1 , Murat Koylu 1 , Tevfik Ilker Akcam 2 , Ayse Gul Ergonul 2 , Pinar Gursoy 3 , Gursel Cok 4 1 Radiation Oncology, Ege University Faculty of Medicine, Izmir, Turkey. 2 Thoracic Surgery, Ege University Faculty of Medicine, Izmir, Turkey. 3 Medical Oncology, Ege University Faculty of Medicine, Izmir, Turkey. 4 Pulmonology, Ege University Faculty of Medicine, Izmir, Turkey Purpose/Objective: The treatment of malignant pleural mesothelioma (MPM) poses a great challenge for oncologists. We planned to investigate the treatment results of trimodal therapy for MPM and the prognostic value of panimmune inflammatory value(PIV) in MPM. Material/Methods: In our study, the data of patients who treated in a single tertiary university hospital between 2021-2023 were evaluated. Initially, each patient underwent induction CT with platinum-based chemotherapy, and after CT, patients without distant metastases underwent P/D and HIPEC according to their eligibility. All patients were treated with IMRT for the involved hemithorax after the surgery, using 45-59.4 Gy RT in 25-30 fx and 9-11 non-coplanar fields. Missing doses in the drain and incision lines were increased by special positioning. Pre-treatment PIVs of the patients were calculated using the (platelet x monocyte x neutrophil)/lymphocyte formula, and patients were grouped as PID-high and PID-low according to the median PID value. Results: Data from 15 patients who met the inclusion criteria were included. The administered median total RT dose was 59 (range 45-60) Gy. Radiation pneumonitis (RP) developed in five patients, 4 of whom had G2 or G3 RP, and a total of 12 (80%) had grade 2-3 fibrosis in the RT-treated lung. Two-year overall survival was 40%, and any progression-free survival (PFS) was 30%. The main progression pattern was distant metastases. The median follow-up time for the entire cohort was 21 months, LRPFS time was 18 months, and distant
Purpose/Objective: Introduction: A recent phase 2 clinical trial by
Gronberg et al. have demonstrated improved survival outcomes with high-dose, twice-daily radiation therapy (RT) for limited-stage small-cell lung cancer (LS-SCLC). However, this regimen has not been widely adopted in routine practice. This study evaluates the real-world experience of dose-escalated RT in LS-SCLC patients treated at two tertiary centers. Material/Methods: Methods: We retrospectively reviewed consecutive LS- SCLC patients treated with concurrent chemoradiation using a high-dose, twice-daily RT regimen (60 Gy in 40 fractions over 4 weeks) between 2020-2023. Baseline characteristics, oncologic outcomes (progression-free survival [PFS], overall survival [OS], patterns of failure, response rates), and RT-related toxicity were evaluated. Dosimetric parameters, including gross tumor volume (GTV) and lung dose, were collected. Results: Results: Thirteen patients were included, with a median age of 59 years and 61.5% female. The median follow-up time was 27 months. The majority (92.3%) completed the planned RT course. The median OS was
Made with FlippingBook - Share PDF online